SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77641.05
875.13 (1.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Zydus Lifesciences Ltd.	Q V PT	1,09,686 Mid Cap	1,124 (2.22%)	21.76	4.22	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,034 Small Cap	836.20 (0.29%)	84.21	4.96	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Wockhardt Ltd.	Q V+ PT	30,660 Small Cap	1,925.35 (2.04%)	143.94	6.22	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Windlas Biotech Ltd.	Q V PT	1,753 Small Cap	856.85 (0.88%)	26.38	3.41	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Wanbury Ltd.	Q V+ PT	1,092 Small Cap	311.65 (-0.27%)	16.51	7.56	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Viyash Scientific Ltd.	Q V PT	11,064 Small Cap	256.45 (1.26%)	62.41	4.09	20.23	2.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Vimta Labs Ltd.	Q V+ PT	2,694 Small Cap	603.95 (0.20%)	33.81	5.72	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Vijaya Diagnostic Centre Ltd.	Q V PT	13,987 Small Cap	1,361.25 (0.24%)	80.86	14.61	15.00	18.43	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Unichem Laboratories Ltd.	Q V PT	3,763 Small Cap	533.85 (-0.11%)	23.67	1.44	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,86,354 Large Cap	4,882 (-0.35%)	86.14	22.16	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Thyrocare Technologies Ltd.	Q V+ PT	9,229 Small Cap	583 (0.54%)	52.35	14.66	10.88	8.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Themis Medicare Ltd.	Q V PT	973 Small Cap	108.80 (3.03%)	N/A	3.62	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Tarsons Products Ltd.	Q V PT	1,655 Small Cap	319.35 (2.67%)	73.04	2.45	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Syngene International Ltd.	Q V+ PT	16,520 Small Cap	413.40 (1.01%)	54.18	3.54	9.45	1.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Syncom Formulations (India) Ltd.	Q V PT	1,216 Small Cap	13.20 (2.01%)	16	2.95	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Suven Life Sciences Ltd.	Q V+ PT	8,314 Small Cap	309.10 (5.05%)	N/A	4.74	-14.30	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Suraksha Diagnostic Ltd.	Q V PT	1,297 Small Cap	248.35 (-0.30%)	40.31	5.3	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Supriya Lifescience Ltd.	Q V+ PT	6,684 Small Cap	856.50 (3.13%)	31.96	5.58	17.45	18.30	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,74,397 Large Cap	1,982.45 (0.27%)	41.33	5.68	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,783 Small Cap	214.55 (2.66%)	4.37	5.09	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Strides Pharma Science Ltd.	Q V+ PT	9,604 Small Cap	1,051.05 (0.87%)	52.3	2.93	3.25	-0.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Solara Active Pharma Sciences Ltd.	Q V PT	2,446 Small Cap	505.35 (-0.33%)	N/A	1.92	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	SMS Pharmaceuticals Ltd.	Q V+ PT	3,567 Small Cap	397.50 (4.36%)	40.72	4.43	13.70	14.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Sigachi Industries Ltd.	Q V+ PT	971 Small Cap	25.92 (1.97%)	N/A	2.04	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Shree Ganesh Remedies Ltd.	Q V PT	798 Small Cap	622.40 (0.15%)	44.89	4.89	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Shilpa Medicare Ltd.	Q V+ PT	11,839 Small Cap	604.75 (-0.09%)	48.65	4.57	7.22	-12.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Shalby Ltd.	Q V PT	1,742 Small Cap	163.55 (1.39%)	15.43	1.4	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Senores Pharmaceuticals Ltd.	Q V+ PT	6,108 Small Cap	1,332.80 (0.49%)	328.57	8.13	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Sanofi India Ltd.	Q V PT	7,743 Small Cap	3,392.80 (0.91%)	24.99	9.93	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,860 Small Cap	4,734.85 (0.41%)	42.11	24.04	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Artemis MedicareServ	300.90	8.55%
Suven Life Sciences	309.10	5.05%
Divis Laboratories	7,781.20	4.86%
SMS Pharmaceuticals	397.50	4.36%
Dr. Lal Pathlabs	1,881.75	4.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Hester Biosciences	2,460.10	-2.57%
Fischer Medical	35.99	-2.31%
3B Blackbio Dx	1,275	-1.63%
Fermenta Biotech	450	-1.37%
Indraprastha Medical	363.50	-1.29%

News about Top Pharma Companies in India

Jul, 2026

Senores Pharmaceutic - Quaterly Results

The turnover zoomed to Rs. 269.90 millions, up 67.33% for the June 2026 quarter as against Rs. 161.30 millions during the year-ago period.Net Profit of the company move down -61.85% to Rs. 10.30 millions from Rs. 27.00 millions in the same quarter last year.The company reported a degrowth in operating Profit to 72.20 millions from 72.30 millions.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	269.90	161.30	67.33	269.90	161.30	67.33	1060.90	385.40	175.27
Other Income	95.50	120.80	-20.94	95.50	120.80	-20.94	663.50	219.90	201.73
PBIDT	72.20	72.30	-0.14	72.20	72.30	-0.14	476.70	147.10	224.07
Interest	22.20	17.60	26.14	22.20	17.60	26.14	69.80	65.20	7.06
PBDT	50.00	54.70	-8.59	50.00	54.70	-8.59	406.90	81.90	396.83
Depreciation	36.10	18.80	92.02	36.10	18.80	92.02	132.30	30.80	329.55
PBT	13.90	35.90	-61.28	13.90	35.90	-61.28	274.60	51.10	437.38
TAX	3.60	8.90	-59.55	3.60	8.90	-59.55	72.10	14.20	407.75
Deferred Tax	0.50	5.00	-90.00	0.50	5.00	-90.00	-12.40	-0.30	4033.33
PAT	10.30	27.00	-61.85	10.30	27.00	-61.85	202.50	36.90	448.78
Equity	460.54	460.54	0.00	460.54	460.54	0.00	460.50	460.50	0.00
PBIDTM(%)	26.75	44.82	-40.32	26.75	44.82	-40.32	44.93	38.17	17.73

Jul, 2026

SMS Pharmaceuticals informs about board meeting

SMS Pharmaceuticals has informed that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve Un-audited Financial Results of the Company for the first quarter ended on June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Thyrocare Tech. - Quaterly Results

The sales figure stood at Rs. 2256.60 millions for the June 2026 quarter. The mentioned figure indicates a growth of about 26.14% as compared to Rs. 1788.90 millions during the year-ago period.Good Net Profit growth of 39.17% reported above the corresponding previous quarter figure of Rs. 360.50 millions to Rs. 501.70 millioins.OP of the company witnessed a marginal growth to 791.20 millions from 604.80 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	2256.60	1788.90	26.14	2256.60	1788.90	26.14	7742.70	6331.00	22.30
Other Income	35.10	39.60	-11.36	35.10	39.60	-11.36	133.90	133.40	0.37
PBIDT	791.20	604.80	30.82	791.20	604.80	30.82	2697.20	2003.60	34.62
Interest	12.60	6.20	103.23	12.60	6.20	103.23	21.80	26.30	-17.11
PBDT	778.60	598.60	30.07	778.60	598.60	30.07	2615.70	1977.30	32.29
Depreciation	112.30	89.50	25.47	112.30	89.50	25.47	511.70	465.20	10.00
PBT	666.30	509.10	30.88	666.30	509.10	30.88	2104.00	1512.10	39.14
TAX	164.60	148.60	10.77	164.60	148.60	10.77	615.90	554.30	11.11
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	43.00	76.60	-43.86
PAT	501.70	360.50	39.17	501.70	360.50	39.17	1488.10	957.80	55.37
Equity	1591.70	529.90	200.38	1591.70	529.90	200.38	1591.70	529.90	200.38
PBIDTM(%)	35.06	33.81	3.71	35.06	33.81	3.71	34.84	31.65	10.07

Jul, 2026

Solara Active Pharma - Quaterly Results

The revenue zoomed 19.57% to Rs. 3816.00 millions for the quarter ended June 2026 as compared to Rs. 3191.50 millions during the corresponding quarter last year.Profit for the quarter ended June 2026 rises by 61.35% to Rs. 169.90 millions from Rs. 105.30 millions.OP of the company witnessed a marginal growth to 639.30 millions from 580.10 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3816.00	3191.50	19.57	3816.00	3191.50	19.57	13689.80	12837.60	6.64
Other Income	19.20	9.80	95.92	19.20	9.80	95.92	58.90	91.40	-35.56
PBIDT	639.30	580.10	10.21	639.30	580.10	10.21	1925.70	2129.80	-9.58
Interest	202.30	239.00	-15.36	202.30	239.00	-15.36	942.40	1148.10	-17.92
PBDT	437.00	341.10	28.11	437.00	341.10	28.11	924.40	981.70	-5.84
Depreciation	267.10	235.80	13.27	267.10	235.80	13.27	996.80	992.50	0.43
PBT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
Equity	480.60	443.40	8.39	480.60	443.40	8.39	445.10	402.50	10.58
PBIDTM(%)	16.75	18.18	-7.83	16.75	18.18	-7.83	14.07	16.59	-15.21

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Zydus Lifesciences Ltd.	1,09,686 Crore
2	Yatharth Hospital & Trauma Care Services Ltd.	8,034 Crore
3	Wockhardt Ltd.	30,660 Crore
4	Windlas Biotech Ltd.	1,753 Crore
5	Wanbury Ltd.	1,092 Crore
6	Viyash Scientific Ltd.	11,064 Crore
7	Vimta Labs Ltd.	2,694 Crore
8	Vijaya Diagnostic Centre Ltd.	13,987 Crore
9	Unichem Laboratories Ltd.	3,763 Crore
10	Torrent Pharmaceuticals Ltd.	1,86,354 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	86.14	22.16	44.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,668	67,559	30.92	4.83	22.42	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,782	94,987	97.82
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	57.56
Aurobindo Pharma Ltd. (M)	Very Good	1,591	89,212	37.52
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,882	1,86,354	35.15
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	22.15
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,309	27,605	80.84	11.01	42.51	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,382	41,675	39.47	9.21	26.67	13.54
Mankind Pharma Ltd. (M)	Very Good	2,605	1,08,129	53.07	6.61	33.20	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	13.52
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,459	1,09,494	20.53	4.89	11.88	32.37
Abbott India Ltd. (M)	Very Good	27,769	59,301	38.21	12.49	26.17	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,144	94,790	29.42	2.48	15.11	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,124	1,09,686	21.76	4.22	13.36	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,982	4,74,397	41.33	5.68	23.70	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Senores Pharmaceutic - Quaterly Results

SMS Pharmaceuticals informs about board meeting

Sun Pharmaceutical Industries informs about press release

Thyrocare Tech. - Quaterly Results

Solara Active Pharma - Quaterly Results

Sanofi India informs about analyst meet

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.